Podcasts about advanced breast cancer

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

Javier Cortés, MD, PhD / Laura Huppert, MD - Novel Uses for Trusted Tools: Investigational Approaches for TROP2-Directed ADCs in Advanced Breast Cancer

What do the latest clinical trial data tell us and how do they impact practice? Credit available for this activity expires: 5/20/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/charting-new-frontiers-advanced-breast-cancer-milestones-2026a1000fu7?ecd=bdc_podcast_libsyn_mscpedu

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. References: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464 Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944 ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521 Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: …

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. References: Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464 Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944 ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521 Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: …

In this podcast, experts Hope S. Rugo, MD, FASCO; Giuseppe Curigliano, MD, PhD; Paolo Tarantino, MD, PhD; and Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS; discuss and debate recently published results of pivotal clinical trials in early-stage, HER2-positive breast cancer and their implications for patient care.

Please visit answersincme.com/CZS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Giuseppe Curigliano, MD, PhD. In this activity, an expert in oncology discusses the differentiation of patients with HER2-low/ultralow/negative advanced breast cancer and treatment with antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Differentiate HER2-low, -ultralow, and -negative advanced breast cancer; Identify patients with HER2-low and -ultralow advanced breast cancer who would benefit from treatment with antibody-drug conjugates; and Apply evidence-based strategies to connect testing to treatment in patients with HER2-low or -ultralow advanced breast cancer.

Send us a textIn this episode, Dr. Jennifer Simmons, Mark Newman, MS, and Dr. Jaclyn Smeaton discuss advancements in breast cancer screening, estrogen and breast cancer, and the gaps in provider education regarding hormone therapy.This conversation also highlights:The implications of removing the “black box” warning from menopausal estrogen products Misconceptions surrounding estrogen and breast cancer risk The nuances of hormone therapy during cancer treatmentInnovative breast cancer screening methods and critiques on the reliance on mammogramsAdvocating for patient empowerment in navigating hormone therapy optionsShow Notes:Learn more about Dr. Jenn Simmons and follow her on Instagram @drjennsimmons! Become a DUTCH Provider today to get access to free educational resources, peer-reviewed and validated research, comprehensive patient reports, and expert clinical support.

Send us a textWhat if cancer didn't have to be eradicated, but could be remembered, monitored, and controlled by the immune system itself?In this episode of Causes or Cures, Dr. Eeks speaks with Dr. Zachary Hartman, the lead researcher who revisited an extraordinary breast cancer vaccine trial conducted over 20 years ago. The trial involved a small group of women with advanced breast cancer. Women who, remarkably, are all still alive today.By analyzing their blood decades later, the research team discovered that these women still carried immune cells capable of recognizing their cancer, suggesting durable immune memory lasting more than two decades. (Study link here.)We discuss:The original breast cancer vaccine trial and what it was designed to do, in plain languageWhat it was like to discover that the women from the trial was still alive more than 20 years laterHow the immune systems of these women continued to recognize cancer cells long after the trialWhat CD27-positive immune cells are and why they matter, explained simplyWhy helper CD4 T cells may be just as important, or more important, than killer CD8 T cells when it comes to cancerWhat happened when researchers combined a CD27-boosting antibody with a cancer vaccine in miceWhat surprised the research team mostThe challenges of translating findings from mice to human trialsWhether cancer could someday be managed long-term by the immune systemHow generalizable this immune memory might be across different cancersWhat this research could mean for how we think about vaccines in a post-pandemic worldThe one key message the researcher hopes the public takes awayWhat's next in this line of researchThis episode offers a rare, hopeful (but scientifically grounded) look at how the immune system may be capable of remembering cancer for decades. Guest Bio: Dr. Zachary C. Hartman is an Associate Professor at Duke University in the Departments of Surgery, Pathology, and Integrative Immunobiology, where he also serves as Director of the Center for Applied Therapeutics and is a member of the Cellular and Molecular Biology and Genetics and Genomics programs. He earned his undergraduate degree from Northwestern University and completed his PhD at Duke University, followed by postdoctoral training in tumor immunology and breast oncology at Duke and the MD Anderson Cancer Center. In 2012, Dr. Hartman returned to Duke to establish a research program focused on tumor immunology and the development of cancer immunotherapies, including therapeutic vaccines, immune agonists, checkpoint inhibitors, antibody-based therapies, and strategies to stimulate anti-tumor immune responses.  Work with me? Perhaps we are a good match. You can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow Public Health is WeirdOr Facebook here.Or X.OnSupport the show

Featuring an interview with Dr Kevin Kalinsky, including the following topics: Patient-Reported Outcomes from the TROPION-Breast01 Study (0:00) Pernas S et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes from the TROPION-Breast01 study. ASCO 2024;Abstract 1006. Indirect Comparison of Sacituzumab Govitecan and Datopotamab Deruxtecan for Advanced Breast Cancer (5:04) Pathak N et al. Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): Safety and efficacy analysis. San Antonio Breast Cancer Symposium 2024;Abstract P1-02-02. BEGONIA: A Phase Ib/II Study of Datopotamab Deruxtecan with Durvalumab as First-Line Treatment for Unresectable Advanced Triple-Negative Breast Cancer (9:53) Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. ESMO 2023;Abstract 379MO. Advances in the Use of TROP2-Targeted Antibody-Drug Conjugates for Breast Cancer: Mechanisms, Clinical Applications and Future Directions (15:35) Tong Y et al. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front Immunol 2024;15:1495675. Abstract CME information and select publications

A recent study by ChristianaCare's Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute shows some areas of Delaware have higher odds of advanced breast cancer.The research explains some of the reasons for the elevated rates, and how that is shaping ChristianaCare's response.This week Delaware Public Media's Joe Irizarry sits down with Dr. Scott Siegel, the lead author and director of Cancer Control & Population Sciences at ChristianaCare's Cawley Center to discuss the research, and what comes next.

When do you first test for ESR1 mutation in hormone receptor (HR)-positive advanced breast cancer (ABC)? Credit available for this activity expires: 8/7/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002782?ecd=bdc_podcast_libsyn_mscpedu

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it's also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it's important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it's also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it's important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

Join this program to get the latest commentary on updates in HER2-positive advanced and metastatic breast cancer. Credit available for this activity expires: 7/29/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002765?ecd=bdc_podcast_libsyn_mscpedu

In this podcast episode, Sara A. Hurvitz, MD, FACP, La-Urshalar B. Brock, FNP-BC, CNM, and Jordan Hill, PharmD, BCOP, discuss the important role of the multidisciplinary team in achieving comprehensive and individualized care of patients with HR-positive/HER2-negative metastatic breast cancer and preexisting comorbidities, including:Key Comorbidities in Patients with HR+/HER2- MBCImpact of PolypharmacyRole of APPs in Comprehensive CareRole of CDK4/6 Inhibitors and Other Treatments for HR+/HER2- MBCUtility of RWE dataCommunicating Treatment Options With Patients and CaregiversUnderstanding Patient Goals and Coordinating With the Multidisciplinary Team to Individualize Treatment and Maximize Quality of LifeLink to full program:https://bit.ly/4jCQe38

Deltra James was diagnosed at 33 with de novo Stage IV, Triple Negative MBC. She is a New England based mama, poet, patient advocate, and co-host of the Empowered Intimacy podcast. In this episode Deltra reads her piece “For Now is As Good As Forever: Dating with Advanced Breast Cancer” from the 2024 “MBC: Advocacy” issue of Wildfire Journal. Her essay is about one woman's experience of dating alongside her metastatic breast cancer diagnosis, and podcasting about it. April and Deltra will discuss being open to sharing cancer stories, cancer's impact on established relationship vows, dating new people after cancer, and empowered intimacy challenges after cancer. This episode contains sexual content.More about Deltra:https://www.instagram.com/deltra_does_it/https://youtube.com/playlist?list=PLQqB9UtXWxPio1JOyDBTn-sA4TIuPRa2o&si=kIXAwVFtnG6mXD7FMore about our episode sponsor Rethink Breast Cancer:https://www.instagram.com/rethinkbreastcancer/https://rethinkbreastcancer.com/find-community?utm_campaign=featured_banner_THERETHINKNETWORK&utm_medium=referral&utm_source=later-linkinbioPurchase the “MBC: Advocacy” issue of Wildfire Magazine: https://www.wildfirecommunity.org/shop/p/family24Buy the Wildfire book Igniting the Fire Within: Stories of Healing, Hope & Humor, Inside Today's Young Breast Cancer Community: https://www.amazon.com/dp/B0BJVJ629F?ref_=pe_3052080_397514860Get the free Wildfire “Hot Flashes” email newsletter: https://www.wildfirecommunity.org/newsletter?rq=newsletterLearn about Wildfire writing workshops: https://www.wildfirecommunity.org/workshopsShop Wildfire merch & more: https://www.wildfirecommunity.org/shop*Free* Get Wildfire and The Burn freebies here: https://www.wildfirecommunity.org/freeMore about Wildfire Magazine: https://www.wildfirecommunity.orghttps://www.instagram.com/wildfire_bc_magazine/https://www.facebook.com/wildfirecommunityInformation on submitting your story for consideration to be published in Wildfire Magazine: https://www.wildfirecommunity.org/submissions

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:https://bit.ly/4jCQe38

In this podcast episode, Allison Butts, PharmD, BCOP, reviews how pharmacists can help in providing comprehensive patient-centric care for patients with HR+/HER2- MBC and preexisting comorbid conditions, including:Common comorbidities and complexities in managing patients with HR+/HER2- MBCTreatment landscape for patients with HR+/HER2- MBCReal-world studies in women with HR+/HER2- MBCMitigation and management of drug interactions and multidisciplinary team coordination treatment selectionPatient goals and coordinating with multidisciplinary team to maximize quality of lifeLink to full program:https://bit.ly/4jCQe38

Please visit answersincme.com/860/95483855-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss practical strategies for integrating antibody-drug conjugates in special populations with HER2-low advanced breast cancer and essential adverse event management approaches. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

Please visit answersincme.com/860/95483855-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss antibody-drug conjugates in HER2-low advanced breast cancer, including current guideline recommendations and evolving treatment considerations to optimize individualized care. Upon completion of this activity, participants should be better able to: Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer; and Outline evidence-based strategies to enhance the management of patients with HER2-low and -ultralow advanced breast cancer.

Please visit answersincme.com/860/95483855-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology and pathology discuss the evolving classification of HER2 status in advanced breast cancer, including HER2 low and HER2 ultralow, and its impact on treatment decisions. Upon completion of this activity, participants should be better able to: Identify strategies to enhance the identification of HER2-low and -ultralow status in patients with advanced breast cancer; and Review guideline-concordant approaches to individualize treatment selection for patients with HER2-low and -ultralow advanced breast cancer,

Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy

Dr. Reni Butler speaks with Dr. Ed Hendrick and Dr. Debbie Monticciolo about the rising rates of metastatic breast cancer and the vital role of early detection through screening. They discuss their latest research, the impact of screening guidelines, and the urgent need to improve access and participation in breast cancer screening. Surveillance, Epidemiology, and End Results Data Show Increasing Rates of Distant-Stage Breast Cancer at Presentation in U.S. Women. Hendrick and Monticciolo. Radiology 2024; 313(3):e241397.  

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Title: Pfizer and BioNTech seek FDA approval for COVID-19 vaccine boosterPfizer and BioNTech have announced that they are seeking authorization from the FDA for a booster dose of their COVID-19 vaccine. The companies have presented data showing that a third dose of the vaccine can significantly increase protection against the Delta variant.##Title: Moderna to supply 100 million more doses of COVID-19 vaccine to the USModerna has reached an agreement with the US government to supply an additional 100 million doses of its COVID-19 vaccine. The company will deliver the doses by the end of the year, helping to boost vaccination efforts across the country.##Title: AstraZeneca's COVID-19 antibody treatment shows promising results in clinical trialsAstraZeneca has announced that its COVID-19 antibody treatment has shown promising results in clinical trials. The treatment, which is designed to prevent severe disease and hospitalization, could provide an important new tool in the fight against the virus.##Title: Novartis receives FDA approval for new treatment for advanced breast cancerNovartis has received FDA approval for a new treatment for advanced breast cancer. The drug, which targets a specific genetic mutation, has been shown to significantly improve progression-free survival in patients with the disease.##Title: Roche announces positive results from phase 3 trial of Alzheimer's drugRoche has announced positive results from a phase 3 trial of its Alzheimer's drug. The drug, which is designed to target the underlying cause of the disease, showed significant improvement in cognitive function and daily living activities in patients with early-stage Alzheimer's.##Title: Johnson & Johnson to invest $6.5 billion in expanding vaccine production capacityJohnson & Johnson has announced plans to invest $6.5 billion in expanding its vaccine production capacity. The company aims to increase production of its COVID-19 vaccine as well as other vaccines in its portfolio, helping to address global supply shortages.##Title: Merck receives FDA approval for new treatment for certain types of lung cancerMerck has received FDA approval for a new treatment for certain types of lung cancer. The drug, which targets a specific genetic mutation, has been shown to improve overall survival in patients with advanced disease.##Title: Gilead Sciences announces collaboration with Novartis on HIV researchGilead Sciences has announced a collaboration with Novartis on HIV research. The companies will work together to develop new treatments for HIV, with a focus on addressing drug resistance and improving outcomes for patients with the virus.## Title: Eli Lilly receives FDA approval for new treatment for migraineEli Lilly has received FDA approval for a new treatment for migraine. The drug, which is administered through an injection, has been shown to provide rapid relief from migraine symptoms and reduce the frequency of attacks in patients with the condition.

Did you know that estrogen receptor-targeting therapies could help reduce chemotherapy exposure and its associated toxicities in advanced HER2-positive disease?   Credit available for this activity expires: 1/29/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002178?ecd=bdc_podcast_libsyn_mscpedu

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstracts presented at the 2024 San Antonio Breast Cancer Symposium:Estrogen Receptor Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerCurrent Guideline Recommendations for When to Pursue ESR1 Mutation Testing Mutations in Patients With HR-Positive/HER2-Negative Advanced Breast CancerChoice and Sequencing of Next Line of Systemic Therapy for ESR1-Mutated Advanced Breast Cancer Based on Tumor Molecular AlterationsOverview of Class-Related and Unique Adverse Events With Approved and Emerging Oral SERDSExpert Recommendations for the Management of Oral SERDs-Related Adverse EventsProgram faculty:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchDana-Farber Cancer InstituteAssociate Professor in MedicineHarvard Medical SchoolBoston, MassachusettsLaura M. Spring, MDBreast Medical OncologistMass General Hospital Cancer CenterHarvard Medical SchoolBoston, Massachusetts Resources:To download the slides associated with this podcast discussion, please visit the program page.

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive deep into the recent FDA approval of Inavolisib for metastatic hormone receptor-positive breast cancer, based on the groundbreaking INAVO120 study. Join us as we chat with Dr. Komal Jhaveri, a medical oncologist and senior author of the study from Memorial Sloan Kettering Cancer Center. We explored the study design, key findings, and the implications of this new treatment option for patients with PIK3CA mutations. Key topics discussed include: •⁠  ⁠Overview of the INAVO120 study and its significance •⁠  ⁠The unique patient population targeted in the study •⁠  ⁠Key findings, including the impressive improvement in progression-free survival (PFS) •⁠  ⁠Side effects and management strategies for patients •⁠  ⁠The importance of genetic testing in treatment decisions Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of breast cancer treatment. Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #OncologyBrothers #BreastCancer #ENAVOLacib #PIK3CA #CancerResearch #MedicalPodcast #Oncology Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Expert discussed the potential of pelareorep, a novel immunotherapeutic agent, in treating advanced or metastatic breast cancer, particularly in HR-positive, HER2-negative patients, and the plans for further clinical development of pelareorep in this indication.

In recognition of Breast Cancer Awareness Month, Dr. Greg Czarnota, a senior scientist and radiation oncologist at Sunnybrook Research Institute in Toronto, discusses his innovative research using focused ultrasound in breast cancer treatment. Dr. Czarnota shares promising results from his phase I clinical trial using focused ultrasound-stimulated microbubbles to enhance radiotherapy in patients with advanced breast cancers. Key points from the conversation include: The origins of Dr. Czarnota's interest in focused ultrasound and its application in enhancing radiotherapy. He shares details of the upcoming phase II clinical trials that will be enrolling patients with inoperable breast cancer. Technical advances with the Arrayus focused ultrasound device could treat larger and more complex tumors. Dr. Czarnota has also developed ultrasound imaging methods to detect cell death. SHOW TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/  

Featuring a slide presentation and related discussion from Dr Priyanka Sharma, including the following topics: Biomarker Assays in the Identification and Prognostication of Patients with Breast Cancer (0:00) Utility of Circulating Tumor DNA in the Prognostication of Localized Breast Cancer (24:28) Treatment of HR-Positive, HER2-Negative Advanced Breast Cancer with a PI3K Mutation (29:46) Utility of Subsequent CDK4/6 Inhibitor After Disease Progression on Initial Therapy (34:57) Treatment of HER2-Low or HER2-Ultralow Metastatic Breast Cancer (40:59) Updated Data and Novel Strategies Involving Trastuzumab Deruxtecan for the Treatment of Advanced Breast Cancer (49:42) Oral Selective Estrogen Receptor Degraders for the Treatment of ER-Positive, HER2-Positive Breast Cancer (51:55) Novel Strategies Involving Antibody-Drug Conjugates and Immunotherapy for Triple-Negative Breast Cancer (58:12) CME information and select publications

Please visit answersincme.com/TBW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in breast cancer offers guidance for determining HER2 status in patients with advanced breast cancer, and shares insights on clinical data and strategies to optimize the use of antibody-drug conjugates (ADCs). Upon completion of this activity, participants should be better able to: Review the guideline recommendations to optimize the identification of patients with HER2-low advanced breast cancer; Outline the clinical implications of the most recent data evaluating the use of available ADCs in the treatment of HER2-low advanced breast cancer; and Identify practical strategies to optimize outcomes with ADC treatment for real-world patient populations with HER2-low advanced breast cancer.

Cochrane has produced several systematic reviews that assess the potential benefits and harms of medicine that might help to prevent bone loss in people with breast cancer. In this podcast, Claire Iannizzi talks with lead author Anne Adams, both from the University Hospital Cologne in Germany, about a review of different bone-modifying agents for reducing bone loss in women with non-metastatic breast cancer, which was published for the first time in July 2024.

Cochrane has produced several systematic reviews that assess the potential benefits and harms of medicine that might help to prevent bone loss in people with breast cancer. In this podcast, Claire Iannizzi talks with lead author Anne Adams, both from the University Hospital Cologne in Germany, about a review of different bone-modifying agents for reducing bone loss in women with non-metastatic breast cancer, which was published for the first time in July 2024.

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including how to incorporate this new class of therapy into treatment plans for patients with HR+/HER2- breast cancer.Presenters:Virginia Kaklamani, MD, DScProfessor of MedicineRuth McLean Bowman Bowers Chair in Breast Cancer Research and TreatmentA.B. Alexander Distinguished Chair in Oncology LeaderBreast Oncology ProgramUT Health San AntonioMD Anderson Cancer CenterSan Antonio, TexasAditya Bardia, MD, MPH, FASCOProfessor of MedicineGeffen School of Medicine at UCLADirector, Breast Oncology ProgramAssistant Chief (Translational Research)Division of Medical OncologyDirector of Translational Research IntegrationUCLA Health Jonsson Comprehensive Cancer CenterLos Angeles, CaliforniaSarah Sammons, MDAssistant Professor of MedicineDana-Farber Cancer Institute Harvard Medical SchoolBoston, Massachusetts Link to full program:https://bit.ly/46hLGcM

In this episode, Dr Joyce O'Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatment plans for patients with HR+/HER2- breast cancer. Topics in this podcast include: Evidence from the monarchE and NATALEE trials of adjuvant abemaciclib and ribociclib, respectively in HR+/HER2- high-risk early breast cancerFactors used to assess risk of recurrence in early breast cancer, including the role of Ki-67 expressionDetermining the need for adjuvant chemotherapy and selection of chemotherapy agentsSelection of patients who may benefit from the addition of adjuvant CDK4/6 inhibitor therapy with endocrine therapyPotential use of preoperative CDK4/6 inhibitorsSequencing therapy for patients with high-risk early breast cancer and a germline BRCA mutationOverview of first-line therapy for advanced HR+/HER2 breast cancerExpert opinion on selection of first-line therapy and factors to considerSelection of second-line therapy based on mutational analysis and recent data from the post-MONARCH trialPresenters:Joyce O'Shaughnessy, MDCelebrating Women Chair in Breast Cancer ResearchBaylor University Medical CenterChair, Breast Disease CommitteeSarah Cannon Research InstituteTexas OncologyDallas, TexasSara A. Hurvitz, MD, FACPProfessor of MedicineHead, Division of Hematology and OncologyDepartment of Medicine, UW MedicineSenior Vice PresidentClinical Research DivisionFred Hutchinson Cancer CenterSeattle, WashingtonErica L. Mayer, MD, MPHDirector of Breast Cancer Clinical ResearchInstitute PhysicianDana-Farber Cancer InstituteAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsLink to full program: https://bit.ly/3XZKp8f

Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient's Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer

It is a tale as old as time, as old as the stars, the heavens and human consciousness itself. Okay, we're exaggerating a bit, but for as long as pharmacology and capitalism have been joined at the hip, the question of "which drug is best" has been at or near the forefront of medical decision-making. With the development of standardised clinical trials and the difficulty of conducting direct head-to-head comparisons, this question has become more difficult to answer conclusively. Nowhere is this epitomised better than with the triptych of available CDK4/6 inhibitors: palbociclib, ribociclib and abemaciclib. A lot of ink and pixels have been devoted to comparing the pivotal trials of these three equally pivotal agents: PALOMA-2, MONALEESA-2 and MONARCH-3, respectively. However, Josh and Michael have brought the definitive and not-at-all rambling answer to this question. Listen on to find out!Links to studies discussed in this episode (subscription may be required):Review Article (Grinshpun et al.): https://www.nature.com/articles/s41523-023-00520-7For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.

Today we are bringing you a special episode that we created in partnership with SHARE Cancer Support. It's an audio version of a live webinar that was done this past February called Report back from San Antonio Breast Cancer Symposium 2023. SABCS is the world's leading breast cancer research meeting where scientists, patient advocates, and others dedicated to working in the field of cancer gather.In this podcast, Dr. Timothy Pluard, director of the Saint Luke's Koontz Center for Advanced Breast Cancer, breaks down the promising research, targeted therapy, the evolving treatment after CDK 4/6 inhibitors, liquid biopsy and more.

In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:Challenges with the pathologic testing for HER2-low expressionOptimal treatment of patients with HER2-low advanced breast cancerRole of TROP-2–targeted therapiesManagement of ADC-associated adverse events to optimize treatment outcomesADCs on the horizon for patients with advanced breast cancerPresenters:Sara M. Tolaney, MD, MPHChief, Division of Breast OncologyDana-Farber Cancer InstituteAssociate Professor of MedicineHarvard Medical SchoolBoston, MassachusettsMelinda Telli, MDProfessor of MedicineStanford University School of MedicineDirector, Breast Cancer ProgramStanford Cancer InstitutePalo Alto, CaliforniaContent based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.Link to full program:https://bit.ly/49WxRBM

Case-based workup and management of another locally advanced breast cancer case in radiation oncology. Featuring guest Dr Alexandra Bennett.

For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.

A new editorial paper was published in Oncotarget's Volume 14 on July 7, 2023, entitled, “Systemic treatment for brain metastasis in HER2- positive advanced breast cancer: what have we learned so far?” In their new editorial, researchers Marta Vaz Batista, José Perez-Gracia, Inês Eiriz, Maria Gion, Antonio Llombart, Sofia Braga, and Javier Cortés from Medica Scientia Innovation Research (MEDSIR) and Hospital Professor Doutor Fernando Fonseca discuss new drugs available for breast cancer (BC) patients with brain metastasis (BM). The better survival of Human Epidermal growth factor receptor-type 2 positive (HER2+) BC patients unmasked the biological predilection of this BC subtype for development of BM. Indeed, central nervous system (CNS) is a frequent metastatic site for HER2+ advanced BC patients. Over the last years, new therapeutic strategies targeting the HER2 protein have been introduced for systemic treatment of HER2+ BC - either tyrosine kinase inhibitors, monoclonal antibodies, or antibody-drug conjugates. Patients with BMs have a poorer outcome, compared with patients without BMs, but their prognosis is also improving with the introduction of new anti HER2+ - targeted therapies. “Our group has been working in the DEBBRAH trial, using trastuzumab deruxtecan for different settings of CNS involvement: stable or progressing BM and/or leptomeningeal carcinomatosis.” The team included patients with HER2+ and HER2-low BC. Activity of trastuzumab-deruxtecan in patients with HER2+ BC and untreated or progressing after local therapy BMs also has been shown in another phase II trial. “The final results are yet to be reported, but so far, we observed intracranial responses in HER2+ BC patients [7].” Read the full editorial: DOI: https://doi.org/10.18632/oncotarget.28435 Correspondence to: Marta Vaz Batista - marta.vaz@hff.min-saude.pt Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28435 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, brain metastasis, HER2+ breast cancer About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Editor-in-Chief, Robert Amdur, MD, discusses RT before, rather than after, mastectomy in patients with locally advanced breast cancer being treated with neoadjuvant chemotherapy. The discussion is based on a paper published in the July 2023 issue of PRO titled “Pathologic Complete Response and Oncologic Outcomes in Locally Advanced Breast Cancers Treated With Neoadjuvant Radiation Therapy: An Australian Perspective” (2023, Issue 4, July/August, PMID: 36599393).